HomeNews

Lupin Q2fy15

Jump to

Lupin Q2 profit up 55%, misses topline & EBITDA estimates

Consolidated net profit of the drug maker jumped 55 percent year-on-year to Rs 630 crore during the quarter led by growth in formulations, US and domestic businesses, and also due to higher other income and lower tax cost.
Lupin Q2 profit seen up 36% on better operating performance

Revenue may rise 23 percent to Rs 3,270 crore in the second quarter of current financial year 2014-15 compared to Rs 2,668 crore in the year-ago period driven by strong growth in US.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Lupin Q2fy15

Lupin Q2 profit up 55%, misses topline & EBITDA estimates

Lupin Q2 profit seen up 36% on better operating performance